胶质瘤中PD-1/PD-L1轴的研究进展与挑战
Research progress and challenges of the PD-1/PD-L1 axis in gliomas.
作者信息
Jiacheng Dong, Jiayue Cui, Ying Guo, Shaohua Wang, Wenhui Liu, Xinyu Hong
机构信息
Department of Neurosurgery, Jilin Provincial Hospital, The First Hospital of Jilin University, 1 Xinmin Street, Changchun, Jilin, 130021, China.
Department of Histology and Embryology, The School of Basic Medicine, Jilin University, 126 Xinmin Street, Changchun, Jilin, 130021, China.
出版信息
Cell Biosci. 2024 Sep 27;14(1):123. doi: 10.1186/s13578-024-01305-6.
The emergence of programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) immunosuppressants provides new therapeutic directions for various advanced malignant cancers. At present, PD-1/PD-L1 immunosuppressants have made significant progress in clinical trials of some gliomas, but PD-1/PD-L1 inhibitors have not yet shown convincing clinical efficacy in gliomas. This article summarizes the research progress of the PD-1 /PD-L1 pathway in gliomas through the following three aspects. It mainly includes the complex expression levels and regulatory mechanisms of PD-1/PD-L1 in the glioma microenvironment, the immune infiltration in glioma immunosuppressive microenvironment, and research progress on the application of PD-1/PD-L1 immunosuppressants in clinical treatment trials for gliomas. This will help to understand the current treatment progress and future research directions better.
程序性死亡蛋白1（PD-1）和程序性死亡配体1（PD-L1）免疫抑制剂的出现为各种晚期恶性肿瘤提供了新的治疗方向。目前，PD-1/PD-L1免疫抑制剂在一些胶质瘤的临床试验中取得了显著进展，但PD-1/PD-L1抑制剂在胶质瘤中尚未显示出令人信服的临床疗效。本文通过以下三个方面总结了PD-1/PD-L1通路在胶质瘤中的研究进展。主要包括PD-1/PD-L1在胶质瘤微环境中的复杂表达水平及调控机制、胶质瘤免疫抑制微环境中的免疫浸润，以及PD-1/PD-L1免疫抑制剂在胶质瘤临床治疗试验中的应用研究进展。这将有助于更好地了解当前的治疗进展和未来的研究方向。
Zotero 插件